MidFirst Bank’s Biogen BIIB Stock Holding History

MidFirst Bank’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.97K	Hold	23	–	–	﹤0.01%	583
2026 Q1	$4.22K	Buy	23 +13	+130%	+$2.4K	﹤0.01%	595
2025 Q4	$1.76K	Buy	+10	New	+$1.63K	﹤0.01%	686

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Amundi Paris, France $413B AUM 44.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

MidFirst Bank's BIIB Position: Q2 2026 in Review

MidFirst Bank held its Biogen (BIIB) position steady in Q2 2026 at 23 shares worth $4.97K. The position accounts for ﹤0.01% of the portfolio, ranked #583.

MidFirst Bank first reported a position in BIIB in Q4 2025 and has held it in 3 quarters since. 842 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

MidFirst Bank held 23 shares of Biogen worth $4.97K as of Q2 2026.
MidFirst Bank left its Biogen share count unchanged in Q2 2026.
Biogen made up ﹤0.01% of MidFirst Bank's portfolio in Q2 2026, its #583 holding.
MidFirst Bank first reported a position in Biogen in Q4 2025 and has held it in 3 quarters since.
842 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on MidFirst Bank's 13F filing for Q2 2026, filed 7 Aug 2026.